Clinical Trial Update: Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 single-arm trial evaluated the immune response to talimogene laherparepvec (T-VEC) in unresected melanoma; results completed and posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Talimogene laherparepvec (talimogene laherparepvec)

Snippet

Sponsor: Amgen | Conditions: Unresected Stage IIIb to IVM1c Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2018-07-18